SEC Company Response from Mawson Infrastructure Group Inc. (MIGI) (CIK 0001218683) (BGDE) — Nov 30, 2018
Mawson Infrastructure Group Inc. (MIGI) (CIK 0001218683)
Date: Nov. 30, 2018 · CIK: 0001218683 · Accession: 0001213900-18-016773
AI Filing Summary & Sentiment
Reasoning
Letter
Wize Pharma, Inc.
24 Hanagar Street
Hod Hasharon, Israel 4527708
November 30, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attn: Jeffrey Gabor
Re:
Wize Pharma, Inc.
Registration Statement on Form S-1
File No. 333- 228516
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Wize Pharma, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 pm, Eastern Time, on December 4, 2018, or as soon thereafter as possible.
The Company hereby confirms that it is aware of its responsibilities under the Act, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the registration statement. The Company hereby acknowledges that:
1) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
/s/ OR EISENBERG
Show Raw Text
CORRESP
1
filename1.htm
Wize Pharma, Inc.
24 Hanagar Street
Hod Hasharon, Israel 4527708
November 30, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attn: Jeffrey Gabor
Re:
Wize Pharma, Inc.
Registration Statement on Form S-1
File No. 333- 228516
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and
Regulations under the Securities Act of 1933, as amended (the “Act”), Wize Pharma, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become
effective at 4:30 pm, Eastern Time, on December 4, 2018, or as soon thereafter as possible.
The Company hereby
confirms that it is aware of its responsibilities under the Act, and the Securities Exchange Act of 1934, as amended, as they relate
to the proposed offering of the securities specified in the registration statement. The Company hereby acknowledges that:
1) should the Securities
and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any action with respect to the filing;
2) the action of
the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company
from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
3) the Company may
not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
Very truly yours,
/s/ OR EISENBERG
Or Eisenberg
Acting Chief Executive Officer and Chief Financial Officer
Cc:
Gregory Sichenzia, Esq.
Avital Perlman, Esq.